ABT 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-07-28

• June 30, 2025Total ChangeImpact of Foreign ExchangeTotal Change Excl. Foreign Exchange

• The 12.2 percent increase in total net sales during the second quarter of 2026, excluding the impact of foreign exchange, was driven by the acquisition of Exact Sciences Corporation (Exact Sciences) and high single-digit growth in Medical Devices and Established Pharmaceutical Products, partially of…

• The 8.2 percent increase in total net sales during the first six months of 2026, excluding the impact of foreign exchange, reflected higher sales in Diagnostic Products, Medical Devices, and Established Pharmaceutical Products, partially offset by lower sales in Nutritional Products. Diagnostic Prod…

• The table below provides detail by sales category for the six months ended June 30. Percent changes are versus the prior year and are based on unrounded numbers.

• (in millions)Six Months Ended June 30, 2026Six Months Ended June 30, 2025Total ChangeImpact of Foreign ExchangeTotal Change Excl. Foreign Exchange

相对上期删除的文字 · 来源:10-Q · 2026-04-29

• The 3.8 percent increase in total net sales during the first quarter of 2026, excluding the impact of foreign exchange, primarily reflected higher product sales in the Medical Devices and Established Pharmaceutical Products segments. Nutritional Products sales primarily declined due to lower sales v…

• The table below provides detail by sales category for the three months ended March 31. Percent changes are versus the prior year and are based on unrounded numbers.

• (in millions)March 31, 2026March 31, 2025Total ChangeImpact of Foreign ExchangeTotal Change Excl. Foreign Exchange

• Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $46 million of sales in the first quarter of 2025 were reclassified from Structural Heart to Electrophysiology.

• In the first three months of 2026, Diagnostic Products sales increased 2.5 percent, excluding the impact of foreign exchange. Growth in Core Laboratory and the inclusion of Exact Sciences' results were partially offset by a decline in Rapid and Molecular Diagnostics. Cancer Diagnostics results inclu…

相对上期新增的文字 · 来源:10-Q · 2026-07-28

• Abbott is involved in various claims, legal proceedings and investigations as described in its Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 10-K”), including those described below (as of June 30, 2026, except where noted below). While it is not feasible to predict the o…

• In the 2025 10-K, Abbott reported that it is a defendant in numerous lawsuits alleging that preterm infants developed necrotizing enterocolitis as a result of being administered Abbott’s preterm infant formula products. Abbott further reported in the 2025 10-K that in a Missouri state court trial he…

• In the 2025 10-K, Abbott reported that six shareholder derivative lawsuits had been pending in a consolidated proceeding, In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation, before the United States District Court for the Northern District of Illinois against certain of Abbot…

相对上期删除的文字 · 来源:10-Q · 2026-04-29

• Abbott is involved in various claims, legal proceedings and investigations, including those described in its Annual Report on Form 10-K for the year ended December 31, 2025.